SMC recommends Napp's bendamustine in CLL, Genzyme's Renvela and ... er, well ... that's all
This article was originally published in Scrip
Of the latest batch of verdicts to come out of Scotland's health technology assessment body, the Scottish Medicines Consortium, only Napp Pharmaceuticals' bendamustine (Levact) received a positive decision for use in chronic lymphocytic leukaemia. The Consortium was convinced that bendamustine was cost-effective for stage B and C CLL in patients who had not responded to the cheaper combination chemotherapies including fludarabine, even though it thought Napp had significantly underestimated the cost of the Quality Adjusted Life Year gain for the drug.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.